Abnormalities in liver function and coagulation profile following the Fontan procedure

Heart

Volumn 82, Issue 1, 1999, Pages 40-46

  Van Nieuwenhuizen, R C ^a   Peters, M ^b   Lubbers, L J ^b   Trip, M D ^a   Tijssen, J G P ^b   Mulder, B J M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NONE

Author keywords

Coagulation; Congenital heart disease; Fontan procedure; Liver function

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; PLASMINOGEN; PROTEIN C; PROTHROMBIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING FACTOR DEFICIENCY; CHILD; CHOLESTASIS; CLINICAL ARTICLE; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; FEMALE; FONTAN PROCEDURE; HEMOSTASIS; HUMAN; LIVER METABOLISM; MALE; POSTOPERATIVE COMPLICATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTHROMBIN TIME; SCHOOL CHILD;

EID: 0033022117     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.82.1.40     Document Type: Article

References (29)

1. 1 Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax 1971;26:240-8.
2. 2 Fontan F, Kirklin JW, Fernandez G. Outcome after a "perfect" Fontan operation. Circulation 1990;81:1520-36.
3. 3 Behrendt DM, Rosenthal A. Cardiovascular status after repair by Fontan procedure. Ann Thorac Surg 1980;29:322-30.
4. 4 Cromme-Dijkhuis AH, Henkens CMA, Bijleveld CMA, et al. Coagulation factor abnormalities as possible thrombotic risk factors after Fontan operations. Lancet 1990;336:1087-90.
5. 5 Kaulitz R, Luhmer I, Bergmann F, et al. Sequelae after modified Fontan operation: postoperative haemodynamic data and organ function. Heart 1997;78:154-9.
6. 6 Cromme-Dijkhuis AH, Hess J, Hählen K, et al. Specific sequelae after Fontan operation at mid-and long-term follow-up. J Thorac Cardiovasc Surg 1993;106:1126-32.
7. 7 Lemmer JH, Coran AG, Behrendt DM, et al. Liver fibrosis (cardiac cirrhosis) five years after modified Fontan operation for tricuspid atresia. J Thorac Cardiovasc Surg 1983;86:757-60.
8. 8 Girod AD, Fontan F, Deville C, et al. Long-term results after the Fontan operation for tricuspid atresia. Circulation 1987;75:605-10.
9. 9 Davis CA, Driscoll DJ, Perrault J, et al. Enteric protein loss after the Fontan operation. Mayo Clin Proc 1994;69:112-14.
10. 10 Feldt RH, Driscoll DJ, Offord KP, et al. Protein-losing enteropathy after the Fontan Operation. J Thorac Cardiovasc Surg 1996;112:672-80.
11. 11 Driscoll DJ, Offord KP, Feldt RH, et al. Five-to fifteen-year follow-up after Fontan operation. Circulation 1992;85:469-96.
12. 12 Jahangiri M, Ross DB, Redington AN, et al. Thromboembolism after the Fontan procedure and its modifications. Ann Thorac Surg 1994;58:1409-14.
13. 13 Teunenbroek A van, Peters M, Sturk A, et al. Protein C activity and antigen levels in childhood. Eur J Pediatr 1990;149:774-8.
14. 14 Matsuda H, Covine E, Hirose H, et al. Acute liver dysfunction after modified Fontan operation for complex cardiac lesions. J Thorac Cardiovasc Surg 1988;96:219-26.
15. 15 Jahangiri M, Shore D, Kakkar V, et al. Coagulation factor abnormalities after the Fontan procedure and its modifications. J Thorac Cardiovasc Surg 1997;113:989-93.
16. 16 Dunn GD, Hayes P, Breen KJ, et al. The liver in congestive heart failure (a review). Am J Med Sci 1973;265:174-89.
17. 17 Hirschmann JV. Pericardial constriction. Am Heart J 1978;96:110-22.
18. 18 Vigano S, Mannucci PM, D'Angelo A, et al. The significance of protein C antigen in acute and chronic liver biliary disease. Am J Clin Pathol 1985;84:454-8.
19. 19 Mair DM, Puga FJ, Danielson GK. Late functional status of survivors of the Fontan procedure performed during the 1970s. Circulation 1992;86(suppl II):106-9.
20. 20 Rosenthal DN, Friedman AH, Kleinman CS, et al. Thromboembolic complications after Fontan operations. Circulation 1995;92(suppl II):287-93.
21. 21 Jonas RA. Intracardiac thrombus after the Fontan procedure [editorial]. J Thorac Cardiovasc Surg 1995;110:1502-3.
22. 22 Hoek JA, Sturk A, ten Cate JW, et al. Laboratory and clinical evaluation of an assay of thrombin-antithrombin III complexes. Clin Chem 1988;34:2058-62.
23. 23 Vukovich T, Teufelsbauer H, Fritzer M, et al. Hemostasis activation in patients with liver cirrhosis. Thromb Res 1995;77:271-7.
24. 24 Tripodi A, Mannucci PM. Markers of activated coagulation and their usefulness in the clinical laboratory. Clin Chem 1996;42:664-9.
25. 25 Bull K. The Fontan procedure: lessons from the past [editorial]. Heart 1998;79:213-14
26. 26 Wilson DG, Wisheart JD, Stuart AG. Systemic thromboembolism leading to myocardial infarction and stroke after fenestrated total cavopulmonary connection. Br Heart J 1995;73:483-5.
27. 27 Connolly SJ, Laupacis A, Gent M, et al. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991;18:349-55.
28. 28 Singer DE, for the BAATAF Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston area anticoagulation trial for atrial fibrillation investigators. N Engl J Med 1990;323:1505-11.
29. 29 Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;i:175-9.